Home > Publications database > Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination. > print

001     292357
005     20250815144951.0
024 7 _ |a 10.1016/j.immuni.2024.07.023
|2 doi
024 7 _ |a pmid:39168129
|2 pmid
024 7 _ |a 1074-7613
|2 ISSN
024 7 _ |a 1097-4180
|2 ISSN
024 7 _ |a altmetric:166508960
|2 altmetric
037 _ _ |a DKFZ-2024-01706
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Li, Zhe
|0 P:(DE-He78)4cbe3abf3c7df5d7fbac1c945e4c2fce
|b 0
|e First author
245 _ _ |a Affinity-independent memory B cell origin of the early antibody-secreting cell response in naive individuals upon SARS-CoV-2 vaccination.
260 _ _ |a New York, NY
|c 2024
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1726143462_25161
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:D130#LA:D130# / 2024 Sep 10;57(9):2191-2201.e5
520 _ _ |a Memory B cells (MBCs) formed over the individual's lifetime constitute nearly half of the circulating B cell repertoire in humans. These pre-existing MBCs dominate recall responses to their cognate antigens, but how they respond to recognition of novel antigens is not well understood. Here, we tracked the origin and followed the differentiation paths of MBCs in the early anti-spike (S) response to mRNA vaccination in SARS-CoV-2-naive individuals on single-cell and monoclonal antibody levels. Pre-existing, highly mutated MBCs showed no signs of germinal center re-entry and rapidly developed into mature antibody-secreting cells (ASCs). By contrast, and despite similar levels of S reactivity, naive B cells showed strong signs of antibody affinity maturation before differentiating into MBCs and ASCs. Thus, pre-existing human MBCs differentiate into ASCs in response to novel antigens, but the quality of the humoral and cellular anti-S response improved through the clonal selection and affinity maturation of naive precursors.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a SARS-CoV-2
|2 Other
650 _ 7 |a affinity maturation
|2 Other
650 _ 7 |a germinal center
|2 Other
650 _ 7 |a humoral immunity
|2 Other
650 _ 7 |a mRNA vaccination
|2 Other
650 _ 7 |a pre-existing memory B cells
|2 Other
650 _ 7 |a somatic hypermutation
|2 Other
700 1 _ |a Obraztsova, Anna
|0 P:(DE-He78)e74839b6d00040170cd36ad1b243979d
|b 1
|e First author
700 1 _ |a Shang, Fuwei
|0 P:(DE-He78)8379c86250c50c0537999a6576e18aa7
|b 2
700 1 _ |a Oludada, Opeyemi
|0 P:(DE-He78)0553af257ddaca21e5e06ea6780b2895
|b 3
700 1 _ |a Malapit, Joshua
|0 P:(DE-He78)e469468b5d6134e74ede38a064bc0ecc
|b 4
700 1 _ |a Busch, Katrin
|0 P:(DE-He78)6695811f3270b3dbe3d06842e2ca55cd
|b 5
700 1 _ |a van Straaten, Monique
|0 P:(DE-He78)604bb0ebdb4e4aa550668663597c9ec8
|b 6
700 1 _ |a Stebbins, Erec
|0 P:(DE-He78)3e1497ece09f8d2c69efc8b106a08f2b
|b 7
700 1 _ |a Murugan, Rajagopal
|0 P:(DE-He78)054f6f018d61d9e639fe25324954e8df
|b 8
700 1 _ |a Wardemann, Hedda
|0 P:(DE-He78)03b354519d912a2724af6b7c9106d1f5
|b 9
|e Last author
773 _ _ |a 10.1016/j.immuni.2024.07.023
|g p. S1074761324003728
|0 PERI:(DE-600)2001966-X
|n 9
|p 2191-2201.e5
|t Immunity
|v 57
|y 2024
|x 1074-7613
856 4 _ |u https://inrepo02.dkfz.de/record/292357/files/1-s2.0-S1074761324003728-main.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/292357/files/1-s2.0-S1074761324003728-main.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:292357
|p VDB
|p OpenAPC
|p openCost
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)4cbe3abf3c7df5d7fbac1c945e4c2fce
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)e74839b6d00040170cd36ad1b243979d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)8379c86250c50c0537999a6576e18aa7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)0553af257ddaca21e5e06ea6780b2895
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)e469468b5d6134e74ede38a064bc0ecc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)6695811f3270b3dbe3d06842e2ca55cd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)604bb0ebdb4e4aa550668663597c9ec8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)3e1497ece09f8d2c69efc8b106a08f2b
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)054f6f018d61d9e639fe25324954e8df
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)03b354519d912a2724af6b7c9106d1f5
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-22
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b IMMUNITY : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-22
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-22
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-22
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b IMMUNITY : 2022
|d 2023-10-22
915 p c |a APC keys set
|2 APC
|0 PC:(DE-HGF)0000
915 p c |a Local Funding
|2 APC
|0 PC:(DE-HGF)0001
915 p c |a DFG OA Publikationskosten
|2 APC
|0 PC:(DE-HGF)0002
915 p c |a DEAL: Elsevier 09/01/2023
|2 APC
|0 PC:(DE-HGF)0125
920 2 _ |0 I:(DE-He78)D130-20160331
|k D130
|l B-Zell-Immunologie
|x 0
920 1 _ |0 I:(DE-He78)D110-20160331
|k D110
|l Zelluläre Immunologie
|x 0
920 1 _ |0 I:(DE-He78)D160-20160331
|k D160
|l Strukturbiologie von Infektion und Immunität
|x 1
920 1 _ |0 I:(DE-He78)D130-20160331
|k D130
|l B-Zell-Immunologie
|x 2
920 0 _ |0 I:(DE-He78)D130-20160331
|k D130
|l B-Zell-Immunologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D110-20160331
980 _ _ |a I:(DE-He78)D160-20160331
980 _ _ |a I:(DE-He78)D130-20160331
980 _ _ |a UNRESTRICTED
980 _ _ |a APC

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21